


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-167)	LAZERTINIB
PRONUNCIATION	laz er' ti nib
THERAPEUTIC CLAIM	Treatment of non-small cell lung cancer (NSCLC)

CHEMICAL NAMES

1. 2-Propenamide, *N*-[5-[[4-[4-[(dimethylamino)methyl]-3-phenyl-1*H*-pyrazol-1-yl]-2-pyrimidinyl]amino]-4-methoxy-2-(4-morpholinyl)phenyl]-
2. *N*-{5-[(4-{4-[(dimethylamino)methyl]-3-phenyl-1*H*-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-methoxy-2-(morpholin-4-yl)phenyl}prop-2-enamide
3. *N*-[5-[[4-[4-[(dimethylamino)methyl]-3-phenyl-1*H*-pyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-(morpholin-4-yl)phenyl]acrylamide

STRUCTURAL FORMULA



MOLECULAR FORMULA	C ₃₀ H ₃₄ N ₈ O ₃
MOLECULAR WEIGHT	554.7
TRADEMARK	None as yet
SPONSOR	Janssen Research & Development
CODE DESIGNATIONS	JNJ-73841937-AAA; YH-25448; C-18112003-G
<u>CAS</u> REGISTRY NUMBER	1903008-80-9
UNII	4A2Y23XK11
WHO NUMBER	10587

SCS